Tildra Launch

Discussion in 'Sun Pharma' started by anonymous, Oct 24, 2017 at 10:58 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    So many employees are looking, but just waiting for the right job. It will be a bloodbath in 2018.
     

  2. anonymous

    anonymous Guest

    Generally agree that virtually anyone with any talent is looking and being very selective so they don't get burned again.

    But I don't agree that it'll be a bloodbath next year.

    It'll be more of a consistent trickle, with, as usual, the best leaving sooner rather than later.
     
  3. anonymous

    anonymous Guest

    It will not be a bloodbath next year because Tilda most likely will not launch in 2018. The SUN employment promises will not be kept and many people will be strung out. If you are OK with hawking Absorica and Ximino, then 2018 should fly by fast. Tilda will launch when there is over ten competitors and data supporting less expensive biologics. If the SUN access team keeps up their impeccable record of success, then SUN will never be able to sell Tildra.
     
  4. anonymous

    anonymous Guest

    Unfortunate, but that's a likely scenario.
     
  5. anonymous

    anonymous Guest

    Has anyone received an offer yet for sales roles?
     
  6. anonymous

    anonymous Guest

    You probably will not hear soon. There is no product to launch. Even SUN is not dumb enough to have a full sales force sell the future with no product lined up. If that actually happens, J&J, Lilly, Abbott, Pfizer should all send Dilip and Abhay a Christmas card of thanks, while they ring the cash register.
     
  7. anonymous

    anonymous Guest


    Why is there no product to launch?
     
  8. anonymous

    anonymous Guest

    No product to launch, but SUN talking about a Tildra buy and bill strategy. This method was not too successful in the past with other failed early biologics. In SUN's hands, less likely for success. Buy and bill pricing model adds to more potential of HCP billing scams and continued SUN spread selling schemes. More trouble ahead.